My CML 與 Cancer iChart 使用情況與統計
Designed by a team of NHS Pharmacists working closely with key CML patient support groups, My CML contains a set of specially designed functions to promote optimal patient outcomes. These include:
- A symptom/side effect tracker. Patients can record how they are feeling on a particular day, either in the form of a diary entry or by recording a score (on a scale of 0-10) for particular symptoms e.g. nausea, diarrhoea, muscle cramps etc.
- A drug interaction checker. Patients or their family member/ carer can check if there are any interactions between their CML medication and other medications. The app uses a traffic light system to tell the user whether there is likely to be an interaction between any two medications and how significant any interaction is likely to be.
- A medication reminder tool. Patients or their family member/ carer can set a daily reminder to help them remember to take the CML medication (and any other medication that they might take regularly). Patients can also record every time they take a dose of their medication to check how good their adherence is using the My Progress function, and generate a graph to share with their healthcare provider.
- The ability to enter key lab test results. Patients or their family member/ carer can record important blood test results such as BCR-ABL PCR, full blood count, kidney function and liver function. Patients can then keep track of their results over time using the tables and graphs in the My Progress section.
- An appointment diary. Patients or their family member/ carer can keep track of all CML-related appointments. It also has a notes function so that patients can record any questions or topics that they might want to talk about to their health care provider.
- Access to up to date CML information including guidelines, information on medicines and various support groups both for CML and for cancers in general.
My CML is designed to help patients achieve improved adherence to treatment, which is particularly important in CML where there is strong evidence that poor adherence can lead to significantly worse clinical outcomes than when high levels of adherence are achieved.
Users of the My CML are reminded to seek a doctor's advice in addition to using My CML and before making any medical decisions.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
Healthcare professionals and patients should use this application to search for potential drug-drug interactions between anti-cancer drugs and other medications. Results are presented as a “Traffic Light” system (red, amber, yellow and green) to indicate the recommendation. A brief summary of each interaction is given along with a grading of the quality of evidence (very low, low, moderate, high). The application is available free of charge and has been developed by Radboudumc in Nijmegen, the Liverpool Drug Interactions Group at the University of Liverpool and Clubzap Ltd.
Requirements:
This is an “offline” application that is downloaded to your device. An internet connection is not required to use the application, but is needed for downloading updates.
Why this application may be useful:
Patients with cancer often take medication in addition to cancer therapy either to aid side effects and symptoms, or to treat co-existing conditions. Many of the drug combinations have the potential to interact and this can affect either the patient's safety or the effectiveness of treatment. For this reason some drug combinations should not be given at all, while other drugs may be used together with caution, possibly requiring adjustments to dosage or time of administration. This application is a guide to interactions that may occur between different anti-cancer drugs and other medications that the cancer patient may be prescribed. The application is regularly updated as new data emerge. Full details about the interactions can be found at www.cancer-druginteractions.org
- Apple App Store
- 免費版
- 醫療
商店排名
- -
My CML與 Cancer iChart 比較排名
比較過去 28 天的 My CML 排名趨勢與 Cancer iChart
排名
無可用數據
My CML VS.
Cancer iChart
12月 11, 2024